Gamma-hydroxybutyrate (GHB) is an endogenous compound, but its presence in postmortem blood presents a challenge when interpreting elevated levels as GHB is misused as a recreational drug and is also produced postmortem. A total of 387 postmortem cases (273 male and 114 female) submitted to the toxicology laboratory between 2010 and 2012 specifically requested the analysis of the ketoacidosis biomarker, beta-hydroxybutyrate (BHB). No reference to GHB use was identified in any of the case files; however, BHB and GHB are measured simultaneously using deuterated GHB as the internal standard (GHB-d 6 ) within a calibration range of 5 -500 mg/L. GHB was not detected or <10 mg/L in 18% of the cases (n 5 68), between 10 and 50 mg/L in 73% of the cases (n 5 283) and between 51 and 193 mg/L in 9% of the cases (n 5 36). The manner of death was classified as accidental (n 5 11), alcohol-related (n 5 237), drug-related (n 5 23), homicide (n 5 1), natural (n 5 91), suicide (n 5 9), medical-related (n 5 1) and undetermined (n 5 14). Six cases had GHB concentrations in excess of 100 mg/L with advanced decomposition changes noted in five of these cases. Moderate-to-advanced decomposition was also noted in 50% (n 5 15) of the cases with GHB concentrations in excess of 50 mg/L but <100 mg/L. Approximately one-third of the blood samples tested contained a preservative and although a higher proportion of these samples had GHB concentrations <10 mg/L or not detected (∼30% preserved versus 11% unpreserved), there were still cases with GHB concentrations >51 mg/L (∼6% preserved versus 11% unpreserved). This study highlights the danger of only using a cutoff to establish endogenous levels compared with exogenous use of GHB in postmortem blood.
Introduction
Gamma-hydroxybutyrate (GHB) is an endogenous molecule to the mammalian tissue; however, it has also been encountered as a recreational drug, a drug of abuse, as well as prescription medication for narcolepsy (1 -3) and as a treatment for alcohol withdrawal syndrome (4 -6) . The drug has caused much debate in recent years, mainly arising from its suspected use in cases of drug-facilitated sexual assault (7) . Today, GHB is still encountered all over the UK in all types of cases ranging from drug driving, recreational club use to drug-related deaths (8 -11) .
At postmortem, the concentration of GHB in the blood increases. There are a number of possible mechanisms that may explain why and how this occurs. Elliott et al. (12) suggest that both putrefaction and microorganisms may play a role. Moriya and Hashimoto (13) , on the other hand, suggests that an increase is caused by the glycolysis of bacteria at postmortem, which was further studied by Nishimura et al. (14) . The precise mechanisms remain unknown and as a consequence, the increase in endogenous GHB concentrations makes interpretation challenging. Cutoff levels ranging from 5 (15) to 50 mg/L (16) have been suggested to aid the differentiation between exogenously ingested GHB and endogenous concentrations. The importance of being able to distinguish between endogenous levels and exogenous intake arises from the molecules rapid degradation in the body (17) and its prevalence in drug-facilitated crimes (7) .
In this retrospective study, cases submitted to the Toxicology Laboratory within Forensic Medicine and Science (FMS) at the University of Glasgow requesting analysis for beta-hydroxybutyrate (BHB) between July 2010 and December 2012 were evaluated. Due to the similarity of their structures (see Figure 1 ), BHB and GHB are analyzed simultaneously using an in-house method initially optimized for the analysis of BHB and then adapted and re-validated to include GHB (18) .
In Scotland, alcohol is one of the major causes of death and in 2010 the laboratory introduced the routine analysis of BHB, recognized as a biomarker for ketoacidosis. Ketoacidosis can occur when fatty acids are broken down or when amino acids are deaminated, and the pH of the body is reduced due to a higher than average concentration of ketone bodies (19) . This can occur in diabetics, alcoholics or as a result of starvation. Alcoholic ketoacidosis is a symptom of chronic ethanol intake and decreased food consumption (18) . A request for BHB analysis implies that the instructing pathologist suspects alcohol, diabetes or a combination of diabetes and alcohol misuse may have played a role in each of the cases included in this study. All cases where GHB was specifically requested, mentioned in the police reports or noted as the cause of death were omitted as the main focus was placed on evaluating only cases where GHB was not implicated.
This study is unique in that no previous publications have evaluated endogenous GHB concentrations of such a specific population.
Methodology
The method used for the simultaneous analysis of BHB and GHB was initially developed by Hassan and Cooper (18) for the analysis of BHB only. This method was then re-validated in accordance with recommended best practice (20) to incorporate GHB (21) . A summary of the method and validation is provided below.
GHB was purchased from Sigma-Aldrich (Poole, UK) and GHB-d 6 , used as internal standard, was purchased from Cerilliant Corporation (Austin, TX). Both the liquid-liquid extraction and gas chromatography-mass spectrometry methods have been published previously (18) . Data were collected in full-scan mode, and ions monitored were m/z 233, 114 and 204 for GHB and m/z 239 and 241 for GHB d 6 . The lower limit of quantification (LLOQ) for GHB is 5 mg/L, selected due to the molecules endogenous nature. In the validation process, recoveries for the method were noted at 40-50%, efficacy and accuracy reported in a range of 83-104%. Furthermore, intra-and inter-day (n ¼ 6 and n ¼ 20, respectively) precision was assessed using five replicates at 20 injections per day. The percentage of the coefficient of variation (% CV) was calculated at 10% and was therefore deemed acceptable (20%) (21) .
Case selection
The Toxicology Laboratory based within FMS at the University of Glasgow receives postmortem cases from all regions of Scotland with the exception of the far northern regions. During the study period in question, the cases included in this study originated from the west of Scotland incorporating the city of Glasgow and surrounding urban areas recognized as the most densely populated region in Scotland.
All postmortem cases submitted to the laboratory for toxicological investigations are recorded within the in-house database, which also incorporates demographic information, pathological findings and the cause of death following case completion. Cases were selected if they had been submitted for the analysis of BHB between July 2010 and December 2012. Access to case information was not possible in all cases as the pathologists were based elsewhere in the country, and so only cases with full details of the pathological findings and final cause of death reported were included. All cases where GHB ingestion was suspected or implicated in the cause of death were omitted.
In addition to details relating to the age, sex, cause and manner of death, information was downloaded from the database to include the date of death, the last time the deceased was seen alive and the date of the postmortem examination. Using these dates, two time intervals were calculated. First, an interval relating to when the deceased was last seen alive to the time the body was discovered ( postmortem interval or PMI) and second, the delay between the declared date of death and postmortem examination was also calculated.
The original analytical data generated at the time of analysis were retrieved from archives. All analytical methods completed within FMS are carried out in batches, so that all samples requiring analysis for BHB from different cases are tested together. Between July 2010 and December 2012, there were a total of 68 batches completed. Each batch includes calibration standards (5 -500 mg/L), negative controls (blank blood and blank water) and positive spiked blood internal controls (50 and 300 mg/L). ChemStation software was used for final data collection and to determine the line of best fit with the equation of the line used to calculate the concentration of GHB in the blood samples.
Both preserved (n ¼ 125, 32%) and unpreserved (n ¼ 262, 68%) blood samples were tested in this study. Paired preserved and unpreserved blood samples are routinely collected in all postmortem cases submitted to FMS. In the initial stages, unpreserved samples were used for the analysis because of the higher collection volume. Following published suggestions by Stephens et al. (22) and Elliott et al. (23) and in-house stability studies (21) , the in-house protocol was amended so that the preferred samples for analysis are preserved blood samples.
Criteria for batch acceptability Each batch was originally checked against a set of criteria that must be met to establish the acceptability and validity of the data. All batches included in this study were rechecked to ensure whether the criteria were met. These included acceptable chromatography, no carryover, a minimum of four data points on the calibration curve, positive controls within three standard deviations of the expected concentration, ion ratios within +20% and a correlation coefficient of 0.99.
Results

Demographics
A total of 387 cases submitted for BHB analysis between July 2010 and December 2012 were selected according to the previously mentioned criteria. These cases consisted of 273 males (70.5%) and 114 females (29.5%) with an average age at death of 52 years for both sexes (male median ¼ 52 years and female median ¼ 54 years).
Sixty-one percentage of cases (n ¼ 237) listed alcohol abuse as the manner of death with the remaining cases classified as acci-
. Figure 2 illustrates a further breakdown of the frequencies of the categories of death for males and females.
The majority of cases (95%) involved a delay of up to 16 days from the date that the individual was last seen alive to completion of the postmortem examination and this included an average of 8 days between the date of death and the postmortem examination taking place. The remaining cases involved delays of between 20 days and 6 months.
GHB concentrations in postmortem blood samples GHB concentrations ranged from 0 to 193 mg/L with mean and median concentrations of 28 and 24 mg/L, respectively. Figure 3 summarizes the frequency of GHB concentrations for all 387 cases across a range of concentrations. Approximately two-thirds of the cases had GHB concentrations 30 mg/L (n ¼ 265, 68.5%). A further 86 cases (22.2%) had GHB concentrations ranging from 31 to 50 mg/L and the remaining 36 cases (9.3%) had concentrations from 51 to .100 mg/L. Table I summarizes details of the 36 cases with elevated GHB concentrations including information relating to the degree of decomposition and the estimated PMI.
Effect of decomposition and PMI Decomposition changes were noted in the majority of cases, but there was a significant variation in the details provided and no scientific way with the information available to assess or categorize the extent of decomposition for all cases.
Five of the six cases with GHB concentrations in excess of 100 mg/L had advanced decomposition changes recorded. Moderate-to-advanced decomposition was reported in 50% (n ¼ 15) of the cases with GHB concentrations in excess of 50 mg/L but ,100 mg/L. Advanced or moderate decomposition was also noted in cases with GHB concentrations ,50 mg/L. With respect to the estimated PMI, or delay between when the individual was last seen alive to completion of the postmortem examination, the available information was not reliable in many cases. The exact timeframe from when the individual was last seen alive to when they were discovered was .2 days for the majority of cases and therefore a significant assumption was made that the date of death was the last day they were seen alive.
The subset of cases with GHB concentrations exceeding 50 mg/L (n ¼ 36) involved estimated postmortem intervals of only a few hours up to 193 days.
Effect of preservative
Sixty-eight percentage of blood samples (n ¼ 262) did not contain a preservative and contained GHB at concentrations ranging from 0 to 158 mg/L with a mean GHB concentration of 22 mg/L. Of the 32% (n ¼ 125) of samples containing a preservative, the GHB concentrations ranged from 0 to 193 mg/L with a mean GHB concentration of 30 mg/L. Figure 4 compares the frequencies with which different concentrations were measured in preserved blood compared with unpreserved blood. A higher proportion of GHB concentrations ,30 mg/L was observed for In this study, 68.5% of the cases, where exogenous GHB was not implicated in the death, had concentrations ,30 mg/L. This increased to 90.7% (n ¼ 351) for concentrations of 50 mg/L or less providing strong support for the use of 50 mg/ L as a cutoff. However, a further 36 cases (9.3%) had concentrations in excess of 50 mg/L and in all cases GHB was not implicated in the death. Kintz et al. (16) reported considerably lower postmortem femoral blood GHB concentrations compared with cardiac blood as summarized in Table I along with postmortem blood concentrations reported in other studies.
Femoral blood samples were collected in all 387 of the cases in this study. The site of collection was not reported in all of the studies. The analysis of postmortem urine samples has been proposed as a means of differentiating between exogenous and endogenous use, but elevated GHB concentrations in postmortem urine have been reported (16, 25) . This is further compounded by the fact that urine is not always available for analysis or indeed suitable due to putrefactive changes in the body.
The postmortem changes described within the postmortem report for all 387 cases were recorded; however, these data were compromised as there was no standardized method used by the pathologists to describe the various stages of decomposition. This has been recognized as a limiting factor in determining the role of decomposition (26) and was most likely the reason why this was not described by the authors of the studies summarized in Table II . Advanced decomposition was reported in five of the six cases with GHB concentrations in excess of 100 mg/L supporting endogenous production as the source of the elevated GHB concentration. However, advanced decomposition changes were also noted in cases with GHB concentrations lower than the proposed cutoff of 50 mg/L and in cases where GHB was below the LLOQ. Moderate or advanced decomposition was also reported in 50% of the cases with GHB concentrations .50 mg/L but ,100 mg/L. Further investigation is required into the role of decomposition and GHB formation, and the mechanisms involved.
It was not possible to investigate the role of the PMI due to the unreliability of available information relating to when the deceased was last seen alive. In many cases, this will never be known as the individual lived alone. With the exception of Moriya and Hashimoto (27) , none of the authors reporting GHB concentrations in postmortem blood provided information relating to the PMI in their cases. The use of preservatives for blood samples is advisable to avoid in vitro formation of postmortem GHB (28) , even though other studies have demonstrated that GHB is stable for an extended period of time (13) . In this study, there were high concentrations of GHB measured in both preserved and unpreserved blood samples. Although a higher proportion of the preserved samples had GHB concentrations ,30 mg/L, when this was extended to include all cases with GHB concentrations lower than the proposed cutoff of 50 mg/L, the prevalence was similar with 88.9% for unpreserved blood and 94.4% for preserved blood. What is not possible to determine from the samples in this study is whether or not the addition of a preservative prevent further production of GHB compared with the samples collected without preservative. Endogenous production of GHB is understood to take place postmortem and continue in vitro ; therefore, storage conditions are of particular importance.
Conclusion
Elevated GHB concentrations were reported in postmortem femoral blood samples where exogenous use of GHB was not implicated in the death. The proposed cutoff level of 50 mg/L to differentiate between exogenous use and endogenous production of GHB effectively identified endogenous levels or endogenous production in the vast majority of the cases (90.7%, n ¼ 351). However, a further 36 cases (9.3%) had concentrations in excess of 50 mg/L with no apparent explanation.
Of these 36, moderate-to-advanced decomposition changes were reported in 20 cases. The lack of standardization, as to how decomposition changes were reported, prevents any further investigation into the potential role of decomposition. It was also not possible to assess any effect that the PMI may have had on the GHB concentrations due to the unreliability of the available data. Further investigation into the mechanisms involved with the formation of GHB postmortem in conjunction with the collection of more reliable data relating to the PMI and decomposition changes would be advantageous when interpreting postmortem GHB concentrations.
There was a higher proportion of preserved blood samples with GHB concentrations ,30 mg/L than unpreserved blood samples and may support the premise of improved stability with the use of a preservative to decrease formation of GHB in vitro. Alternatively, this may simply reflect the actual GHB concentration in those cases where GHB was measured in the preserved blood sample. A comparison between paired preserved and unpreserved blood samples collected postmortem would provide an opportunity to investigate the role of a preservative in preventing or decreasing in vitro formation of GHB in postmortem blood.
The use of a cutoff for postmortem blood concentrations of GHB and assessment of the role of decomposition are important when interpreting the significance of an elevated GHB concentration. Interpretation of the majority of cases with elevated GHB will clearly indicate endogenous formation of GHB, but there are always cases that will continue to present a challenge.
